SUPRIYA2023-07-012023-09-30 SUPRIYA2023-07-012023-09-30 SUPRIYA2023-07-012023-09-30in-bse-fin:OneOperatingExpenses01Member SUPRIYA2023-07-012023-09-30in-bse-fin:FourOperatingExpenses01Member SUPRIYA2023-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543434 SUPRIYA NA Supriya Lifescience Limited Equity 2023-04-01 2024-03-31 2023-11-07 2023-10-27 INR Millions Half yearly 15:15:00 16:40:00 2023-11-07 2023-11-07 true Cash Flow Indirect Not applicable Single segment Manufacturer of Active Pharmaceuticals Ingredients 2023-07-01 2023-09-30 Unaudited Standalone 1400950000.00 24670000.00 1425620000.00 507030000.00 0.00 109360000.00 175020000.00 4600000.00 39810000.00 292020000.00 1127840000.00 297780000.00 0.00 297780000.00 85380000.00 -26440000.00 58940000.00 0.00 238840000.00 0.00 0.00 0.00 0.00 238840000.00 -1380000.00 237460000.00 0.00 0.00 160970000.00 2 2.97 2.97 0.00 0.00 2.97 2.97 Notes:- 1. The Unaudited Standalone financial results of the Company for the quarter & half year ended September 30, 2023 have been prepared in accordance with the Indian Accounting Standards ( Ind As ) as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended. 2. The above Unaudited standalone financial results of the Company for the quarter & half year ended September 30, 2023 have been reviewed by the Audit Committee on 07th November, 2023 and thereafter approved by the Board of Directors at their meeting held on 07th November, 2023. 3. The Company has adopted Ind AS 116 Leases effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019. 4. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation. 5. The standalone financial results include the results for the quarter ended 30 September 2023 being the balancing figure between the Unaudited figures in respect of the half year ended September 30,2023 and the published unaudited year to date figures up to the first quarter of the current financial year which were subject to limited review by us. Single segment 2023-04-01 2023-09-30 Unaudited Standalone 2721160000.00 53850000.00 2775010000.00 982310000.00 0.00 106280000.00 329300000.00 10150000.00 79370000.00 543440000.00 2050850000.00 724160000.00 0.00 724160000.00 185010000.00 15200000.00 200210000.00 0.00 523950000.00 0.00 0.00 0.00 0.00 523950000.00 13190000.00 537140000.00 0.00 0.00 160970000.00 2 6.51 6.51 0.00 0.00 6.51 6.51 Other Expenses 292020000.00 Other Expenses 543440000.00 2514810000.00 1164580000.00 0.00 12660000.00 569530000.00 0.00 569530000.00 60070000.00 4321650000.00 988250000.00 0.00 848350000.00 1040420000.00 117670000.00 5560000.00 44800000.00 2056800000.00 1063600000.00 4108650000.00 8430300000.00 160970000.00 7370760000.00 7531730000.00 7531730000.00 0.00 52610000.00 52610000.00 38160000.00 151950000.00 242720000.00 1010000.00 551970000.00 25170000.00 578150000.00 69330000.00 8370000.00 655850000.00 898570000.00 8430300000.00 10150000.00 169460000.00 -1710000.00 0.00 -64440000.00 -70000.00 -70000.00 19250000.00 0.00 -90310000.00 0.00 -17100000.00 12870000.00 79370000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 46770000.00 0.00 0.00 0.00 0.00 0.00 -2950000.00 0.00 67680000.00 791840000.00 0.00 0.00 0.00 232180000.00 0.00 559660000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 530490000.00 0.00 316570000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 46770000.00 0.00 0.00 0.00 -800290000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 165240000.00 0.00 1720000.00 0.00 10150000.00 0.00 0.00 -177110000.00 -417740000.00 0.00 -417740000.00 1575820000.00 1158080000.00 -1840000.00 17630000.00 -460000.00 4440000.00